Novel drug targets in clinical development for heart failure
详细信息 查看全文
- 作者：Melvin George (1)
Muthukumar Rajaram (1)
Elangovan Shanmugam (1)
Thangavel Mahalingam VijayaKumar (2) - 关键词：Heart failure ; New drugs ; Targets ; Istaroxime ; Omecamtiv mecarbil ; Relaxin
- 刊名：European Journal of Clinical Pharmacology
- 出版年：2014
- 出版时间：July 2014
- 年：2014
- 卷：70
- 期：7
- 页码：765-774
- 全文大小：
- 参考文献：1. Heart Failure . http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/heart-failure/.Accessed 16 Sep 2013
2. Bui AL, Horwich TB, Fonarow GC (2011) Epidemiology and risk profile of heart failure. Nat Rev Cardiol 8:30-1 CrossRef
3. WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Heart disease and stroke statistics-010 update: a report from the American Heart Association. Circulation 121:e46–e215 CrossRef
4. Nieminen MS, Brutsaert D, Dickstein K et al (2006) EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 27:2725-736 CrossRef
5. Norton C, Georgiopoulou VV, Kalogeropoulos AP, Butler J (2011) Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis 54:78-5 CrossRef
6. Ferrandi M, Barassi P, Tadini-Buoninsegni F et al (2013) Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. Br J Pharmacol 169:1849-861 CrossRef
7. Micheletti R, Mattera GG, Rocchetti M et al (2002) Pharmacological profile of the novel inotropic agent (E, Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303:592-00 CrossRef
8. Khan H, Metra M, Blair JEA et al (2009) Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev 14:277-87 CrossRef
9. Blair JEA, Macarie C, Ruzyllo W et al (2008) Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am J Ther 15:231-40 CrossRef
10. Shah SJ, Blair JEA, Filippatos GS et al (2009) Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 157:1035-041 CrossRef
11. Aditya S, Rattan A (2012) Istaroxime: A rising star in acute heart failure. J Pharmacol Pharmacother 3:353-55 CrossRef
12. Garg V, Frishman WH (2013) A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF. Cardiol Rev 21:155-59 CrossRef
13. Malik FI, Morgan BP (2011) Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol 51:454-61 CrossRef
14. Meijs MFL, Asselbergs FW, Doevendans PA (2012) Omecamtiv mecarbil: a promising new drug in systolic heart failure. Eur J Heart Fail 14:232-33 CrossRef
15. Teerlink JR, Clarke CP, Saikali KG et al (2011) Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 378:667-75 CrossRef
16. Cleland JGF, Teerlink JR, Senior R et al (2011) The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378:676-83 CrossRef
17. Avanzas P, Bayes-Genis A, de Isla LP, Sanchis J, Heras M (2013) Summary of the Clinical Studies Reported in the European Society of Cardiology Congress 2013 (31 August -4 September, 2013, Amsterdam, The Netherlands). Rev Esp Cardiol Engl Ed 66:879.e1-79.e9
18. Clinical Trials.gov http://clinicaltrials.gov/ct2/show/NCT01786512?term=omecamtiv+mecarbil&rank=4.Accessed 17 March 2014
19. Cernaro V, Lacquaniti A, Lupica R, et al (2013) Relaxin: New Pathophysiological Aspects and Pharmacological Perspectives for an Old Protein. Med Res Rev
20. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M (2010) Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 7:75-2 CrossRef
21. Teerlink JR, Metra M, Felker GM et al (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373:1429-439 CrossRef
22. Metra M, Cotter G, Davison BA et al (2013) Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61:196-06 CrossRef
23. Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU. http://www.novartis.com/newsroom/media-releases/en/2014/1756879.shtml. Accessed 17 March 2014
24. Edwards BS, Zimmerman RS, Schwab TR, Heublein DM, Burnett JC Jr (1988) Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62:191-95 CrossRef
25. Saito Y (2010) Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 56:262-70 CrossRef
26. Ishikawa C, Tsutamoto T, Wada A et al (2005) Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1?week of infusion in patients with congestive heart failure. J Cardiovasc Pharmacol 46:513-18 CrossRef
27. Hayashi M, Tsutamoto T, Wada A et al (2001) Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 37:1820-826 CrossRef
28. Shono M, Yoshimura M, Nakayama M et al (2007) Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J Off J Jpn Circ Soc 71:1040-046
29. Liang F, O’Rear J, Schellenberger U et al (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49:1071-078 CrossRef
30. Chen HH, Glockner JF, Schirger JA, Cataliotti A, Redfield MM, Burnett JC Jr (2012) Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. J Am Coll Cardiol 60:2305-312 CrossRef
31. Suwa M, Seino Y, Nomachi Y, Matsuki S, Funahashi K (2005) Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the “real world-of therapy. Circ J Off J Jpn Circ Soc 69:283-90
32. Nomura F, Kurobe N, Mori Y et al (2008) Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study. Circ J Off J Jpn Circ Soc 72:1777-786
33. Hata N, Seino Y, Tsutamoto T et al (2008) Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study. Circ J Off J Jpn Circ Soc 72:1787-793
34. Sezai A, Hata M, Niino T et al (2010) Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 55:1844-851 CrossRef
35. Selby VN, Teerlink JR (2013) What’s new in the treatment of acute heart failure? Curr Cardiol Rep 15:393 CrossRef
36. Mitrovic V, Seferovic PM, Simeunovic D et al (2006) Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27:2823-832 CrossRef
37. Lüss H, Mitrovic V, Seferovic PM et al (2008) Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 155:1012.e1- CrossRef
38. Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure - Full Text View - ClinicalTrials.gov.http://www.clinicaltrials.gov/ct2/show/NCT01661634?term=TRUE+AHF&rank=1.Accessed 24 Sep 2013
39. Kushnir A, Marks AR (2010) The ryanodine receptor in cardiac physiology and disease. Adv Pharmacol San Diego Calif 59:1-0 CrossRef
40. Aronson D, Krum H (2012) Novel therapies in acute and chronic heart failure. Pharmacol Ther 135:1-7 CrossRef
41. Shan J, Betzenhauser MJ, Kushnir A et al (2010) Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. J Clin Invest 120:4375-387 CrossRef
42. Sacherer M, Sedej S, Waku?a P et al (2012) JTV519 (K201) reduces sarcoplasmic reticulum Ca2+ leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol 167:493-04 CrossRef
43. Lehnart SE, Mongillo M, Bellinger A et al (2008) Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118:2230-245
44. http://www.controlled-trials.com/ISRCTN14227980. Accessed 17 March 2014
45. Sawyer DB, Caggiano A (2011) Neuregulin-1β for the treatment of systolic heart failure. J Mol Cell Cardiol 51:501-05 CrossRef
46. Zhao YY, Sawyer DR, Baliga RR et al (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261-0269 CrossRef
47. Li B, Zheng Z, Wei Y et al (2011) Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats. Cardiovasc Diabetol 10:69 CrossRef
48. Liu X, Gu X, Li Z et al (2006) Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48:1438-447 CrossRef
49. Jabbour A, Hayward CS, Keogh AM et al (2011) Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 13:83-2 CrossRef
50. Gao R, Zhang J, Cheng L et al (2010) A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 55:1907-914 CrossRef
51. Valluri A, Struthers AD, Lang CC (2013) Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure. Curr Heart Fail Rep(Nov 15)
52. McMurray JJV, Pitt B, Latini R, Maggioni AP et al (2008) Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1:17-4 CrossRef
53. Solomon SD, Shin SH, Shah A et al (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J 32:1227-234 CrossRef
54. Gheorghiade M, B?hm M, Greene SJ et al (2013) Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA J Am Med Assoc 309:1125-135 CrossRef
55. Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure - Full Text View - ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00853658?term=aliskiren+AND+heart+failure&rank=2. Accessed 17 Mar 2014
56. Abstract 19378: First Experience with Concomitant AT1 and Neprilysin (NEP 24.11) Inhibition with LCZ696 in Patients with Chronic Heart Failure -- Kobalava et al. 122 (10021): A19378 -- Circulation . http://circ.ahajournals.org/cgi/content/meeting_abstract/122/21_MeetingAbstracts/A19378.Accessed 14 March 2014
57. Solomon SD, Zile M, Pieske B et al (2012) The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387-395 CrossRef
58. McMurray JJV, Packer M, Desai AS et al (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 15:1062-073 CrossRef
59. Ather S, Respress JL, Li N, Wehrens XHT (2013) Alterations in ryanodine receptors and related proteins in heart failure.Biochim Biophys Acta
60. Bers DM (2008) Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 70:23-9 CrossRef
61. Jessup M, Greenberg B, Mancini D et al (2011) Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2-??ATPase in patients with advanced heart failure. Circulation 124:304-13 CrossRef
62. Zsebo K, Yaroshinsky A, Rudy JJ et al (2014) Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 114:101-08 CrossRef
63. A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure - Full Text View - ClinicalTrials.gov .http://www.clinicaltrials.gov/ct2/show/study/NCT01643330?term=CUPID+study&rank=4&show_locs=Y#locn. Accessed 17 Mar 2014.
64. Niederseer D, Thaler CW, Niederseer M, Niebauer J (2013) Mismatch between heart failure patients in clinical trials and the real world. Int J Cardiol
65. Van Spall HGC, Toren A, Kiss A, Fowler RA (2007) Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA J Am Med Assoc 297:1233-240 CrossRef
66. Collins SP, Levy PD, Lindsell CJ et al (2009) The rationale for an acute heart failure syndromes clinical trials network. J Card Fail 15:467-74 CrossRef
67. McDonagh TA, Komajda M, Maggioni AP et al (2009) Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure. Eur J Heart Fail 13:1253-260
68. Search of: istaroxime - List Results - ClinicalTrials.gov. istaroxime&show_flds=Y" class="a-plus-plus">http://www.clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&submit_fld_opt=on&term=istaroxime&show_flds=Y. Accessed 19 Sep 2013
69. Search of: omecamtiv mecarbil - List Results - ClinicalTrials.gov .http://www.clinicaltrials.gov/ct2/results?term=omecamtiv+mecarbil&Search=Search. Accessed 19 Sep 2013
70. Search of: carperitide - List Results - ClinicalTrials.gov . http://www.clinicaltrials.gov/ct2/results?term=carperitide&Search=Search. Accessed 19 Sep 2013
71. Search of: relaxin - List Results - ClinicalTrials.gov .http://www.clinicaltrials.gov/ct2/results?term=relaxin&Search=Search. Accessed 19 Sep 2013
72. Search of: cinaciguat - List Results - ClinicalTrials.gov .http://www.clinicaltrials.gov/ct2/results?term=cinaciguat&Search=Search. Accessed 19 Sep 2013
73. Search of: SERCA2a - List Results - ClinicalTrials.gov .http://www.clinicaltrials.gov/ct2/results?term=SERCA2a&Search=Search. Accessed 19 Sep 2013
74. Cooper TJ, Guazzi M, Al-Mohammad A et al (2013) Sildenafil in Heart Failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. Eur J Heart Fail 15:119-22 CrossRef
75. Mylona P, Cleland JG (1999) Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail 1:197-00 CrossRef
76. Handoko ML, de Man FS, Vonk-Noordegraaf A (2011) The rise and fall of endothelin receptor antagonists in congestive heart failure. Eur Respir J 37:484-85 CrossRef
77. Felker GM, Benza RL, Chandler AB et al (2003) Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 41:997-003 CrossRef
78. Triposkiadis F, Parissis JT, Starling RC, Skoularigis J, Louridas G (2009) Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opin Investig Drugs 18:695-07 CrossRef
79. Valania G, Singh M, Slawsky MT (2011) Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists? Curr Heart Fail Rep 8:198-05 CrossRef
80. Teerlink JR, Iragui VJ, Mohr JP et al (2012) The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf Int J Med Toxicol Drug Exp 35:233-44 CrossRef
81. Gheorghiade M, Greene SJ, Filippatos G et al (2012) Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 14:1056-066 CrossRef
82. Press Announcements-gt;?FDA approves Adempas to treat pulmonary hypertension. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm370866.htm. Accessed 17 March 2014.
83. Hartog JWL, Willemsen S, van Veldhuisen DJ et al (2011) Effects of alagebrium, an advanced glycationendproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail 13:899-08 CrossRef - 作者单位：Melvin George (1)
Muthukumar Rajaram (1)
Elangovan Shanmugam (1)
Thangavel Mahalingam VijayaKumar (2)
1. Cardiac Clinical Trials & Research, Department of Cardiology, SRM MCH &RC, Kattankulathur, Chennai, Tamil Nadu, India, 603203
2. Interdisciplinary School of Indian System of Medicine, SRM University, Kattankulathur, Chennai, Tamil Nadu, India, 603203 - ISSN：1432-1041
文摘
Background Heart Failure continues to be a leading cause of mortality and morbidity worldwide. The dismal prognosis of patients in acute heart failure (AHF) can be altered only by exploring novel drug molecules. Although the treatment for chronic heart failure (CHF) has seen remarkable progress, there is still a need to develop molecules that could improve the long-term survival outcomes. Purpose To review the drug targets for acute and chronic heart failure and the molecules acting on these targets. Methods The article discusses on the mechanism of how the potential drug targets can be modulated to alter the pathophysiological processes in heart failure. Current evidence on molecules acting on these targets has also been described from published literature using the PubMed and Clinical Trials.gov databases. Results Some of the molecules that are currently being explored for AHF includeomecamtiv mecarbil which activates cardiac myosin ATPase, istaroxime an ionotropicagent that activates SERCA2a pump activity, ularitide and carperitide which are ANP(atrial natriuretic peptide) analogues and recombinant relaxin. Some of the targets forCHF include stabilization of ryanodine receptors, renin inhibition, neprilysin inhibition, neuregulins and SERCA2a gene therapy. Conclusion Clinical trials in heart failure must be designed to minimize the risk of “drug failures.-Nevertheless, it is hoped that in the days to come, drugs with superior efficacy and safety will eventually be produced from the surge of molecules that are in the pipeline.